The U.S. Senate's Special Committee on Aging will hear testimony on Johnson & Johnson subsidiary DePuy's hip recall as it focuses on patient safety in the approval process for medical devices.

This week isn't going to get any better for DePuy Inc., as the Johnson & Johnson (NYSE:JNJ) subsidiary is set to have its dirty laundry aired in front of a Senate panel tomorrow.
The U.S. Senate's Special Committee on Aging announced that the Warsaw, Ind.-based company's massive hip replacement system recall will be front and center during its examination of the FDA and its role in "protecting patient safety as part of the medical device approval process," according to a prepared release.
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on...
Electromed founder, chairman & CEO Robert Hansen announces his retirement after 20 years leading...
St. Jude Medical's shares get a 2% lift from an upgrade by a Goldman Sachs analyst.
Just weeks before a $2.3 billion acquisition by Asahi Kasei closed, the Securities & Exchange...
Boston Scientific's Synergy bioabsorbable drug-eluting stent proves just as good as its leading and...